Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Broncus HoldingBRNHF 43 EBITDA Margin % is 619.15% as of Dec. 2025. GuruFocus rates BRNHF with a GF Score™ of 43/100. The stock has 7 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Broncus Holding ranks worse than 98.28% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Broncus Holding's EBITDA for the
six
months ended in Dec. 2025 was $-9.15 Mil. Broncus Holding's Revenue for the
six
months ended in Dec. 2025 was $-1.48 Mil. Therefore, Broncus Holding's EBITDA margin for the quarter that ended in Dec. 2025 was 619.15%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Broncus Holding EBITDA Margin % Related Terms
Broncus Holding EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Broncus Holding's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRNHF vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Broncus Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Broncus Holding EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Broncus Holding's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Broncus Holding's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Broncus Holding (BRNHF) has a EBITDA Margin % of 619.15% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Broncus Holding and its competitors. According to the industry distribution chart, Broncus Holding ranks #801 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 98.3%.
Is Broncus Holding's EBITDA Margin % too high?
Broncus Holding's current EBITDA Margin % is 619.15%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. Broncus Holding's value of 619.15% is 8133.4% above this industry median. Based on the distribution chart, Broncus Holding ranks #801 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Broncus Holding has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Broncus Holding's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Broncus Holding ranks #801 out of 815 companies for EBITDA Margin %. This places Broncus Holding in the lower half of its industry. The industry median EBITDA Margin % is 7.52. Broncus Holding's value of 619.15% is 8133.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Broncus Holding's current EBITDA Margin % of 619.15% is 8133.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Broncus Holding and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Broncus Holding's current EBITDA Margin % is 619.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Broncus Holding stock overvalued right now?
Broncus Holding (BRNHF) has a current EBITDA Margin % of 619.15%. The current EBITDA Margin % is 619.15% and 8133.4% above the Medical Devices & Instruments industry median of 7.52. Broncus Holding's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Broncus Holding (BRNHF), the current EBITDA Margin % is 619.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Broncus Holding Corp is focused on provision of interventional treatment of Chronic Obstructive Pulmonary Disease and lung cancer. It engages in the field of Interventional Pulmonology, providing solutions for lung diseases in China and globally. Its products portfolio includes the InterVapor Thermal Vapor Treatment System the only implantable medical device to treat COPD; BroncAblate Radiofrequency Ablation System the transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation Radiofrequency Ablation System the self-developed targeted radiofrequency ablation system in China to reduce the risk of acute exacerbation of COPD. Geographically, the company operates in Chinese Mainland; European Union; and Other Regions.
43GF Score
Get the complete analysis for BRNHF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRNHF has been successfully added to your 
